Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR 195.00
+12.10 (6.62%)
Aug 20, 2026, 5:35 PM CET
Sartorius Stedim Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,005 | 2,968 | 2,780 | 2,776 | 3,493 | 2,887 | |
Revenue Growth | 3.75% | 6.74% | 0.16% | -20.53% | 20.98% | 51.14% |
Cost of Revenue | 1,657 | 1,622 | 1,573 | 1,542 | 1,675 | 1,334 |
Gross Profit | 1,349 | 1,345 | 1,207 | 1,234 | 1,817 | 1,553 |
Selling, General & Admin | 655.8 | 662.7 | 650.1 | 617.6 | 612.3 | 531.9 |
Research & Development | 135.5 | 133.1 | 144.1 | 129.5 | 132.4 | 110.5 |
Other Operating Expenses | -14 | 11.4 | 16.5 | 17.5 | 18.2 | -9.6 |
Operating Expenses | 777.3 | 807.2 | 810.7 | 764.6 | 762.9 | 632.8 |
Operating Income | 571.2 | 538.1 | 396 | 469.4 | 1,054 | 920.2 |
Interest Expense | -124.6 | -138.1 | -148 | -115.4 | -18.2 | -10.2 |
Interest & Investment Income | 2.8 | 11.6 | 18.9 | 6.2 | 0.5 | 0.3 |
Earnings From Equity Investments | -2.2 | -2.2 | -8.6 | - | - | - |
Currency Exchange Gain (Loss) | -7.3 | -7.3 | 6.6 | -13.3 | -32.8 | 12.3 |
Other Non Operating Income (Expenses) | -16.2 | -16.1 | -12.9 | -4.3 | -4.6 | -37.1 |
EBT Excluding Unusual Items | 423.7 | 386 | 252 | 342.6 | 999.3 | 885.5 |
Merger & Restructuring Charges | - | - | - | - | - | -20.3 |
Other Unusual Items | -12.8 | -12.8 | -32.8 | 59.3 | 131.1 | -218.5 |
Pretax Income | 410.9 | 373.2 | 219.2 | 401.9 | 1,130 | 646.7 |
Income Tax Expense | 117.2 | 107.3 | 40.7 | 89.2 | 250.5 | 232.4 |
Earnings From Continuing Operations | 293.7 | 265.9 | 178.5 | 312.7 | 879.9 | 414.3 |
Minority Interest in Earnings | -1.1 | -0.3 | -3.4 | -2.4 | -3.8 | 0.1 |
Net Income | 292.6 | 265.6 | 175.1 | 310.3 | 876.1 | 414.4 |
Net Income to Common | 292.6 | 265.6 | 175.1 | 310.3 | 876.1 | 414.4 |
Net Income Growth | 29.93% | 51.69% | -43.57% | -64.58% | 111.41% | 23.36% |
Shares Outstanding (Basic) | 97 | 97 | 97 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 97 | 97 | 97 | 92 | 92 | 92 |
Shares Change | -0.19% | 0.54% | 5.01% | -0.00% | -0.01% | -0.00% |
EPS (Basic) | 3.01 | 2.73 | 1.81 | 3.37 | 9.51 | 4.50 |
EPS (Diluted) | 3.01 | 2.73 | 1.81 | 3.37 | 9.51 | 4.50 |
EPS Growth | 30.17% | 50.88% | -46.26% | -64.58% | 111.45% | 23.51% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 394.3 | 299 | 475.3 | 272.8 | 181.7 | 377.9 |
Free Cash Flow Per Share | 4.06 | 3.07 | 4.91 | 2.96 | 1.97 | 4.10 |
Dividend Per Share | 0.690 | 0.690 | 0.690 | 0.690 | 1.440 | 1.260 |
Dividend Growth | 0% | 0% | 0% | -52.08% | 14.29% | 85.29% |
Gross Margin | 44.87% | 45.33% | 43.41% | 44.46% | 52.03% | 53.79% |
Operating Margin | 19.01% | 18.13% | 14.24% | 16.91% | 30.19% | 31.87% |
Profit Margin | 9.74% | 8.95% | 6.30% | 11.18% | 25.08% | 14.35% |
Free Cash Flow Margin | 13.12% | 10.08% | 17.10% | 9.83% | 5.20% | 13.09% |
EBITDA | 816.4 | 778.1 | 629.3 | 657.7 | 1,197 | 1,031 |
EBITDA Margin | 27.17% | 26.22% | 22.64% | 23.70% | 34.27% | 35.73% |
D&A For EBITDA | 245.2 | 240 | 233.3 | 188.3 | 142.5 | 111.2 |
EBIT | 571.2 | 538.1 | 396 | 469.4 | 1,054 | 920.2 |
EBIT Margin | 19.01% | 18.13% | 14.24% | 16.91% | 30.19% | 31.87% |
Effective Tax Rate | 28.52% | 28.75% | 18.57% | 22.20% | 22.16% | 35.94% |